Arcturus Therapeutics, Inc. is an RNA medicines company. Our versatile RNA therapeutics platform enables development of all types of RNA medicines including small interfering RNA (siRNA), messenger RNA (mRNA), antisense RNA, microRNA and gene editing therapeutics.
Our proprietary unlocked nucleomonomer agent (UNA) Oligomer™ technology can be used to target any gene in the human genome, as well the genes of other species, such as viruses, for therapeutic purposes.
Our patented Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) nanoparticle delivery system allows safe and efficient in vivo delivery of all RNA medicines.
We use our innovative technologies to develop best-in-class RNA medicines that treat rare diseases. We also collaborate with industry leaders including Janssen Pharmaceuticals, Inc. (a Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc. to develop novel RNA therapeutics.
December 6, 2016
Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA–based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
November 1, 2016
nature Biotechnology and nature Reviews Drug Discovery
October 4, 2016
Big Pharma Goes Small With Moves Into Incubator Space